Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.82+3.94%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GLUE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
fund operations and capital expenditures into 2029 | The company aims to fund operations and capital spending into 2029. | Intact | cash and equivalents fall below levels needed to fund operations through 2029 | Cash and cash equivalents: $90.104M FY2026-Q2; GAAP. Published target: Maintain sufficient cash and equivalents to fund operations and capex into 2029. Target period is not explicitly aligned with this observation. Date unavailable90,104,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development story, not an established compounder, because the company is loss-making and its results have been weak. The thesis is in a watch state: programs are advancing, but recent performance remains well below its industry cohort.
The valuation model tags expectations as justified, but with low confidence. GLUE carries a 4.19 premium versus peers, while the expectations gap is negative and optionality is the main valuation driver. That suggests the market gives weight to future program potential even as current execution is weak.
Near term, earnings risk is elevated after recent misses, and the snapshot flags a high chance of another miss next quarter. Over the multi-year view, MRT-8102, MRT-6160, and MRT-2359 are moving through clinical development, though higher research spending and weak financial performance leave execution risk in place. Recent litigation adds another concern.
The multi-year thesis depends on planned Phase 2 studies starting and clinical programs continuing to advance, including progress with MRT-6160 and its milestone payments. Near term, guidance, employment data, and results from healthcare bellwethers could shape the backdrop; further guidance cuts or a weakening jobs trend would be unfavorable.
GLUE has meaningful clinical-development potential, but that potential is set against losses, weak recent performance, repeated earnings misses, and litigation. The 1-to-3-year view hinges on continued study progress and whether financial execution improves. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
GFORCE-1 study results in H2 2026 | Positive clinical data and partnerships support future progress. | Intact | GFORCE-1 study results are negative or delayed beyond H2 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
achieve ~23% revenue growth in FY27 | A primary condition in Monte Rosa Therapeutics, Inc.'s published investment case. The stated target is >=23% YoY revenue growth. | Broken | YoY revenue growth falls below ~23% in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.84 → $-1.86 · observed estimates
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.84 | $58,210,286 | 5 / 5 |
| 2026-07-25 | $-1.84 | $58,210,286 | 5 / 5 |
| 2026-07-26 | $-1.81 | $58,171,430 | 7 / 7 |
| 2026-07-27 | $-1.84 | $58,210,286 | 5 / 5 |
| 2026-07-28 | $-1.84 | $58,210,286 | 5 / 5 |
| 2026-07-29 | $-1.84 | $58,210,286 | 5 / 5 |
| 2026-07-30 | $-1.81 | $58,171,430 | 7 / 7 |
| 2026-07-31 | $-1.81 | $58,171,430 | 7 / 7 |
| 2026-08-01 | $-1.84 | $58,210,286 | 5 / 5 |
| 2026-08-02 | $-1.81 | $58,171,430 | 7 / 7 |
| 2026-08-03 | $-1.81 | $58,171,430 | 7 / 7 |
| 2026-08-04 | $-1.81 | $58,171,430 | 7 / 7 |
| 2026-08-05 | $-1.84 | $58,210,286 | 5 / 5 |
| 2026-08-06 | $-1.81 | $58,171,430 | 7 / 7 |
| 2026-08-07 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-08 | $-1.83 | $81,440,000 | 7 / 5 |
| 2026-08-09 | $-1.83 | $81,440,000 | 7 / 5 |
| 2026-08-10 | $-1.83 | $81,440,000 | 7 / 5 |
| 2026-08-12 | $-1.88 | $57,067,430 | 7 / 7 |
| 2026-08-13 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-14 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-15 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-16 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-17 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-18 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-19 | $-1.86 | $56,924,571 | 5 / 5 |
| 2026-08-20 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-21 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-22 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-23 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-24 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-25 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-26 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-27 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-28 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-29 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-30 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-08-31 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-01 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-02 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-03 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-04 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-05 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-06 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-07 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-08 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-09 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-10 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-11 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-12 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-13 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-14 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-15 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-16 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-17 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-18 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-19 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-20 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-21 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-22 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-23 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-24 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-25 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-26 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-27 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-28 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-29 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-09-30 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-10-01 | $-1.90 | $57,067,429 | 5 / 5 |
| 2026-10-02 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-03 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-04 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-05 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-06 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-07 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-08 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-09 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-10 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-11 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-12 | $-1.97 | $53,934,000 | 6 / 6 |
| 2026-10-13 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-14 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-15 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-16 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-17 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-18 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-19 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-20 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-21 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-22 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-23 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-24 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-25 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-26 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-27 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-28 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-29 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-30 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-10-31 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-11-01 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-11-02 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-11-03 | $-1.86 | $64,608,000 | 7 / 7 |
| 2026-11-04 | $-1.86 | $64,608,000 | 7 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.